Switch theme
Sign up to access all valuation multiples
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
2017
22
Last FY Revenue n/a
LTM EBITDA -$33.7M
$75.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aardvark Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$33.7M.
In the most recent fiscal year, Aardvark Therapeutics achieved revenue of n/a and an EBITDA of -$22.8M.
Aardvark Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aardvark Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$33.7M | XXX | -$22.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$36.8M | XXX | -$22.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$34.4M | XXX | -$20.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aardvark Therapeutics's stock price is $10.
Aardvark Therapeutics has current market cap of $226M, and EV of $75.9M.
See Aardvark Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $75.9M | $226M | XXX | XXX | XXX | XXX | $-4.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aardvark Therapeutics has market cap of $226M and EV of $75.9M.
Aardvark Therapeutics's trades at n/a EV/Revenue multiple, and -3.3x EV/EBITDA.
Equity research analysts estimate Aardvark Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aardvark Therapeutics has a P/E ratio of -6.6x.
See valuation multiples for Aardvark Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $226M | XXX | $226M | XXX | XXX | XXX |
| EV (current) | $75.9M | XXX | $75.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | -3.3x | XXX | XXX | XXX |
| EV/EBIT | -2.1x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.6x | XXX | -11.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAardvark Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
Aardvark Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aardvark Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aardvark Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 71% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aardvark Therapeutics acquired XXX companies to date.
Last acquisition by Aardvark Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Aardvark Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aardvark Therapeutics founded? | Aardvark Therapeutics was founded in 2017. |
| Where is Aardvark Therapeutics headquartered? | Aardvark Therapeutics is headquartered in United States of America. |
| How many employees does Aardvark Therapeutics have? | As of today, Aardvark Therapeutics has 22 employees. |
| Who is the CEO of Aardvark Therapeutics? | Aardvark Therapeutics's CEO is Dr. Tien-Li Lee, M.D.. |
| Is Aardvark Therapeutics publicy listed? | Yes, Aardvark Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Aardvark Therapeutics? | Aardvark Therapeutics trades under AARD ticker. |
| When did Aardvark Therapeutics go public? | Aardvark Therapeutics went public in 2025. |
| Who are competitors of Aardvark Therapeutics? | Similar companies to Aardvark Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Aardvark Therapeutics? | Aardvark Therapeutics's current market cap is $226M |
| Is Aardvark Therapeutics profitable? | Yes, Aardvark Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aardvark Therapeutics? | Aardvark Therapeutics's last 12 months EBITDA is -$33.7M. |
| What is the current EV/EBITDA multiple of Aardvark Therapeutics? | Current EBITDA multiple of Aardvark Therapeutics is -2.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
